1 not yet recruiting, 1 recruiting, 1 terminated, 1 unknown. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Amyloid Light-chain Amyloidosis: new trials by email Literature Review of Amyloid Light-chain Amyloidosis trials Research Report on Amyloid Light-chain Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study Daratumumab/daratumumab and hyaluronidase-fihj, Pomalidomide, Dexamethasone - Amyloid Light-chain Amyloidosis | Not applicable | Unknown | Yongyong MA | 20 | 2024-03-01 | 2024-06-12 |
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) SAR445514 - Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | Phase 1 | Terminated | Sanofi | 32 | 2023-05-15 | 2026-05-27 |
Immunoglobulin Light-chain Amyloidosis (4) · Multiple Myeloma (1)
Amyloidosis (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Metabolic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Plasma Cell (4) · Nutritional and Metabolic Diseases (4) · Paraproteinemias (4) · Proteostasis Deficiencies (4) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
daratumumab (2) · Dexamethasone (1) · darlin protein, Dictyostelium (1) · pomalidomide (1)
Case Comprehensive Cancer Center (1) · Rajshekhar Chakraborty, MD (1) · Sanofi (1) · Yongyong MA (1)
United States (2) · Australia (1) · Belgium (1) · China (1) · Czechia (1) · Hungary (1) · Italy (1) · Spain (1) · United Kingdom (1)
Rajshekhar Chakraborty, MD (1) · Sandra Mazzoni, DO (1) · Yongyong Ma, MD (1)